Evidence map›Paper›PMID 29250435›Full record

ArticleNPJ vaccines2016

Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination.

Sarah M Tete, Florian Krammer, Sarah Lartey, Geir Bredholt, John Wood, Steinar Skrede, Rebecca J Cox

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Sarah M TeteDepartment of Clinical Science, The Influenza Centre, University of Bergen, Bergen, Norway.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sarah LarteyDepartment of Clinical Science, The Influenza Centre, University of Bergen, Bergen, Norway.
Geir BredholtDepartment of Clinical Science, The Influenza Centre, University of Bergen, Bergen, Norway.
John WoodNational Institute for Biological Standards and Control, Hertfordshire, UK.
Steinar SkredeSection for Infectious Diseases, Haukeland University Hospital, Bergen, Norway.
Rebecca J CoxDepartment of Clinical Science, The Influenza Centre, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NOUniversity of Bergen · NOIcahn School of Medicine at Mount Sinai · USNational Institute for Biological Standards and Control · GB

Funding

Understanding Human B Cell Responses to Influenza to Improve the Influenza U19AI109946 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RAVETCH, JEFFREY VICTOR · 2014 to 2018
$9.6M
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS U19 AI109946
6 · The paper itself

Abstract

Traditionally, neutralising antibodies that are directed to the major surface glycoprotein hemagglutinin (HA) head domain are measured as surrogate correlates of protection against influenza. In addition to neutralization, hemagglutinin-specific antibodies may provide protection by mediating antibody-dependent cellular cytotoxicity (ADCC). During the 2009 pandemic, vaccination induced HA-specific antibodies that were mostly directed to the conserved HA stalk domain. However, the protective role of these antibodies has not been investigated in detail. We quantified the HA head and stalk-specific antibodies, their avidity, ability to neutralise virus and activate natural killer cells in an ADCC assay. We analyzed sera obtained from 14 healthcare workers who had low hemagglutination inhibition (HI) antibody titres at 3 months after pandemic H1N1 vaccination as well as from 22 controls. Vaccination resulted in a HA stalk dominant antibody response in both low responders and controls. Revaccination of low responders, 5 months later, resulted in a boost in antibodies, with HA head-specific antibodies dominating the response. Comparative analysis of head and stalk antibody avidities revealed that stalk-specific antibodies were qualitatively superior. Furthermore, stalk-specific antibodies mediated virus neutralization and had significantly higher ADCC activity than head-specific antibodies. Despite the head and stalk-specific antibodies being lower in low responders, they had comparable antibody avidity, ADCC functionality and neutralising capacity to those of controls who had high HI titres post-vaccination. Thus, our study has demonstrated that HA stalk-specific antibodies may have an important role in protection through neutralization and ADCC in low responders who do not maintain seroprotective HI antibodies.

Identifiers

PMID29250435
PMCPMC5707877
OpenAlexW2478958226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.